Hugh Thompson, MD
Internal Medicine · Charleston, SCNPI 1275610578
Payments from drug & device makers
Across 191 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$377
- Lilly USA, LLC$370
- Pfizer$345
- Amgen$208
- GSK$173
- Boston Scientific$158
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,19099%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $377 |
| Lilly USA, LLC | 22 | $370 |
| Pfizer | 23 | $345 |
| Amgen | 12 | $208 |
| GSK | 9 | $173 |
| Boston Scientific | 4 | $158 |
| AbbVie(2 entities) | 10 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $154 |
| E.r. Squibb & Sons, L.L.C. | 9 | $140 |
| Boehringer Ingelheim | 8 | $129 |
| Johnson & Johnson | 6 | $91 |
| Exact Sciences | 4 | $85 |
| AstraZeneca | 6 | $79 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Novartis | 4 | $65 |
| Abbott | 2 | $52 |
| Vital Connect, Inc | 1 | $51 |
| Bayer | 3 | $50 |
| Dexcom, Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Amarin Pharma, Inc. | 3 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $35 |
| Sunovion Pharmaceuticals Inc. | 3 | $33 |
| Astellas Pharma US Inc | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Philips North America LLC | 1 | $25 |
| Radius Health, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$116
How this compares
$3,218 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 163 | $178,996 |
| EliquisApixaban | 94 | $118,183 |
| OzempicSemaglutide | 80 | $101,714 |
| JardianceEmpagliflozin | 44 | $43,943 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $32,058 |
| JanuviaSitagliptin Phosphate | 28 | $24,732 |
| TrulicityDulaglutide | 12 | $20,620 |
| MyrbetriqMirabegron | 14 | $18,328 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $15,827 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $14,921 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $12,086 |
| XareltoRivaroxaban | 16 | $11,572 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $8,958 |
| FarxigaDapagliflozin Propanediol | 11 | $8,506 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $370 | $199,616175 claims |
| PfizerEliquis | $345 | $118,18394 claims |
| Novo NordiskOzempic | $377 | $101,71480 claims |
| Boehringer IngelheimJardiance, Glyxambi | $129 | $49,70455 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $173 | $39,83544 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $18,32814 claims |
| AstraZenecaFarxiga, Symbicort | $79 | $12,89427 claims |
| Johnson & JohnsonXarelto | $91 | $11,57216 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $12 | $8,95823 claims |
| Esperion Therapeutics, Inc.Nexletol | $67 | $4,41111 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $19 | $3,18140 claims |
| AbbVieSynthroid | $155 | $3,05560 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Charleston
- Jan BasileCharleston$278K
- James ThomasCharleston$154K
- John CleekCharleston$136K
- Shakaib RehmanCharleston$94K
- Leonard AlsfeldCharleston$91K
- Samuel Schumann IiiCharleston$48K
- Brett TomashitisCharleston$36K
- Scott SandsCharleston$25K
- Laura KinneyCharleston$20K
- Andrew SchreinerCharleston$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.